AstraZeneca

The firm invests with a strategic mandate rather than a pure financial-return objective. Equity stakes are often tied to an option or first-refusal right on the underlying asset, giving AstraZeneca a clinical readout before committing to a full acquisition. This structure allows the venture team to price risk differently than a fund constrained by LP return horizons.

It is a China-focused co-investment vehicle formed with China International Capital Corporation. The fund targets early-stage and growth-stage biotech, diagnostics, and digital-health companies in China, combining AstraZeneca's scientific diligence with CICC's onshore regulatory and capital-markets access. The structure functions as a distinct limited-partner fund open to additional institutional investors.

The venture mandate extends beyond therapeutics into diagnostics, medical devices, and AI-enabled drug-discovery platforms. Investments are designed to complement the core oncology, cardiovascular, respiratory, and rare-disease franchises, with a growing allocation toward digital tools that support clinical-trial execution and real-world evidence generation.

The $39 billion Alexion deal in 2021 created a dedicated rare-disease business unit with its own business-development and R&D budget. The subsidiary operates with some P&L autonomy, allowing it to pursue bolt-on acquisitions and venture investments in complement-inhibitor and rare-neurology platforms without competing against the broader corporate portfolio for capital allocation.

Ultimate investment authority sits with CEO Pascal Soriot and the senior executive team. Day-to-day venture and business-development decisions are delegated to the corporate development and strategy group, which evaluates therapeutic-fit, pricing, and regional partnership structures. Large acquisitions such as Alexion require board and shareholder-level governance.

The firm primarily executes direct equity investments and structured co-investment vehicles like the CICC fund. There is no public record of a fund-of-funds strategy. The venture group operates as a direct investor on company cap tables rather than as an LP in external biotech funds.

Co-investment with peer pharmaceutical companies is rare but occurs through shared-risk oncology partnerships. The long-standing collaboration with Merck & Co. on Lynparza and Koselugo is the most prominent example, where development costs and commercial rights are split by indication rather than by a pooled fund structure.